Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alexion Pharmaceuticals, Inc.
Alexion Reports First Quarter 2009 Results
May 15th, 2009
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced financial results for the quarter ended March 31, 2009. First Quarter 2009 Financial Results: For the three months ended March 31, 2009, Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) reported net product sales of Soliris® of $81.3 million, compared to $45.5 million for the same period in 2008. Soliris was approved in the United States and European Union in 2007 and is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (“PNH”), an ultra-rare, debilitating and life-threatening blood disease. The Company reports both GAAP and non-GAAP results....
Source: Health Business Week (2009-05-15)
|
